棘白菌素类抗真菌药在移植受者中的群体药动学研究进展  

Progress in population pharmacokinetic study of echinocandin antifungal drugs in transplant recipients

作　　者：唐莲 钱卿[2] 胡楠[2] 杨旭萍 陈荣[2] 王莉英[2] TANG Lian;QIAN Qing;HU Nan;YANG Xu-ping;CHEN Rong;WANG Li-ying(Department of Pharmacy,the Second Affiliated Hospital,Nantong University,Jiangsu Nantong 226001,China;Department of Pharmacy,the First People's Hospital of Changzhou,Jiangsu Changzhou 213003,China)

机构地区：[1]南通大学第二附属医院药剂科,江苏南通226001 [2]常州市第一人民医院药学部,江苏常州213003

出　　处：《临床药物治疗杂志》2023年第2期17-21,共5页Clinical Medication Journal

基　　金：江苏省药学会-奥赛康医院药学基金项目(A202021);南通市卫生和计划生育委员会科研课题计划资助(QA2020006)。

摘　　要：移植受者因使用免疫抑制剂及长疗程广谱抗菌药物易发生侵袭性真菌病,且近年来发病率有逐年升高的趋势。棘白菌素类新型抗真菌药具有抗真菌活性强、安全性高、抗真菌谱广等特点。本文通过文献检索,查阅国内外移植受者中棘白菌素类抗真菌药群体药动学研究的相关文献,总结了移植受者应用棘白菌素类后影响药物动学参数的因素包括人口学特征、肝功能、合并用药、手术时间及移植物体积等,从而为采用群体药物动学模型指导移植受者应用棘白菌素类抗真菌药个体化治疗提供参考。Transplant recipients are prone to invasive fungal disease due to the use of immunosuppressants and broadspectrum antibiotics, and the incidence has increased year by year recently. Echinocandins, as new antifungal drugs, have strong antibacterial activity, high safety, and broad antibacterial spectrum. This paper collected literature on the population pharmacokinetics of echinocandins in transplant recipients. The factors that affected the population pharmacokinetic parameters of echinocandins in transplant recipients were summarized, including demographic characteristics, liver function, concomitant medication, operation time and graft volume, etc. It will provide a reference for guiding the individualized treatment of echinocandins transplant recipients with through a population pharmacokinetic model.

关 键 词：棘白菌素类 群体药物代谢动力学 移植受者 

分 类 号：R878.5[医药卫生—运动医学]